Theravance Biopharma, Inc. (TBPH)

NASDAQ: TBPH · Real-Time Price · USD

16.23

+0.97 (6.36%)

At close: Mar 31, 2026, 4:00 PM EDT

15.91

-0.32 (-1.97%)

After-hours: Mar 31, 2026, 4:16 PM EDT

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Discovery (Research), Development and Commercialization of Human Therapeutics	107.46M	64.38M	57.42M	51.35M	55.31M
Discovery (Research), Development and Commercialization of Human Therapeutics Growth	66.92%	12.12%	11.84%	-7.17%	-23.03%
Total	107.46M	64.38M	57.42M	51.35M	55.31M
Total Growth	66.92%	12.12%	11.84%	-7.17%	-23.03%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States	74.96M	64.38M	57.20M	51.12M	55.27M
United States Growth	16.44%	12.55%	11.89%	-7.51%	-21.40%
Europe	32.50M	-	223.00K	222.00K	38.00K
Europe Growth	-	-	0.45%	484.21%	-97.53%
Total	107.46M	64.38M	57.42M	51.35M	55.31M
Total Growth	66.92%	12.12%	11.84%	-7.17%	-23.03%

Source: S&P Global Market Intelligence.